|
References
1. Davis GL, Albright JH, Cook SF, et al.. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology 1998;28:390A.
2. Bedosa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
3. Schlichting P, Holund B, Poulsen H. Liver biopsy in chronic aggressive hepatitis - diagnostic reproducibility in relation to size of specimen. Scand J Gastroenterol 1983;18:27-32.
4. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JGC. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut 1999;45:129-133.
5. Dufour DR (ed.): National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Guidelines for use and interpretation of laboratory tests in hepatocellular injury. Washington DC: National Academy of Clincal Biochemistry, 2001. (also available at www.nacb.org /lmpg/hepatic_lmpg.stm)
6. Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liv Dis 1986;6:129-137.
7. Munoz SJ. Prothrombin time in fulminant hepatic faliure. Gastroenterology 1991;100:1480-1481.
8. Dufour DR, Teot L. Laboratory identification of ischemic hepatitis (shock liver). Clin Chem 1988;34:1287.
9. Singer AJ, Carracio TR, Mofenson HC. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 1995;26:49-53.
10. Harrison PM, O'Grady JG, Keays RT, Alexander GJ, Williams R. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ 1990;301:964-968.
11. Kovacs MJ, Wong A, MacKinnon K, et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71:727-730.
12. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002;36:659-665.
13. Horn KD, Wax P, Schneider SM, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Am J Clin Pathol 1999;112:351-357.
14. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:1516-1522.
15. Kim WR, Brown RS, Terrault NA, El-Serag H: Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-242.
16. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
17. Marcellin P, Asselah T, Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-S56.
18. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-S46.
19. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111.
20. Bonis PAL, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001;344:452-454.
21. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alpha 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.
22. Imbert-Bismut F, Ratziu AV, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with chronic hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-1075.
23. Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis; a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002;97:1419-1425.
24. Patel K, Gordon SC, Oh E, Smith K, McHutchison JG. A non-invasive panel of serum fibrosis markers can reliably differentiate hepatitis C patients with minimal fibrosis from those with fibrosis stages F2-F4. Hepatology 2002;36:Abstract 770
25. Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection. Am J Gastroneterol 1997;92:1302-1304.
26. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-992.
27. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002;36:S3-S20.
|